论文部分内容阅读
AIM: To study whether etodolac enantiomers have pharmacokinetic difference after oral administration. METHODS: Fourteen rats, divided into two groups randomly, were orally given S-(+)- or R-(-)-etodolac at a single dose of 20 mg/kg, respectively. Blood samples were collected before and at 5, 10, 20, 30 min and 1, 3, 6, 12, 24, 48, 72 h after treatment. The plasma samples were analyzed with a high-performance liquid chromatographic method. RESULTS: The calibration curves were linear in the range of 0.5-50.0 mg/L (r=0.9999) to S-(+)-etodolac and 2.0-200.0 mg/L (r=0.9999) to R-(-)-etodolac, respectively. The main pharmacokinetic parameters of S-(+)- and R-(-)-etodolac were as follows: t1/2(λz)18±4 h vs 19.4±2.2 h, tmax 3.3±2.6 h vs 4±4 h; Cmax 29±6 mg/L vs97±14 mg/L, AUC0-t 706±100 h·mg·L-1 vs 2940±400 h·mg·L-1, CL(s) 0.030±0.006 L·kg-1·h-1 vs 0.0065±0.0010 L·kg-1·h-1 and V/F 0.25±0.22 L·kg-1 vs 0.03±0.05 L·kg-1. There was no significant difference in t1/2(λz) and tmax between S-(+)-
AIM: To study whether etodolac enantiomers have pharmacokinetic difference after oral administration. METHODS: Fourteen rats divided into two groups randomly, were orally given S - (+) - or R - (-) - etodolac at a single dose of 20 mg / kg, respectively. Blood samples were collected before and at 5, 10, 20, 30 min and 1, 3, 6, 12, 24, 48, 72 h after treatment. The plasma samples were analyzed with a high-performance liquid chromatographic method . RESULTS: The calibration curves were linear in the range of 0.5-50.0 mg / L (r = 0.9999) to S - (+) - etodolac and 2.0-200.0 mg / The main pharmacokinetic parameters of S - (+) - and R - (-) - etodolac were as follows: t1 / 2 (λz) 18 ± 4 h vs 19.4 ± 2.2 h, tmax 3.3 ± 2.6 h vs 4 ± 4 h; Cmax 29 ± 6 mg / L vs 97 ± 14 mg / L, AUC0-t 706 ± 100 h · mg · L-1 vs 2940 ± 400 h · mg · L-1, CL L · kg -1 · h -1 vs 0.0065 ± 0.0010 L · kg -1 · h -1 and V / F 0.25 ± 0.22 L · kg -1 vs 0.03 ± 0.05 L · kg -1 There was no significant difference in t1 / 2 (λz) and tmax between S - (+) -